Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 17/20 | 0.57 |
| ▸ | ITGA4 | P13612 | 17/20 | 0.57 |
| ▸ | C1R | P00736 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14626721 | 0.91 | ITGB1 (0.55) | ITGB1ITGA4C1RNPC1TP53 | |
| SCHEMBL14591719 | 0.89 | ITGB1 (0.53) | ITGB1ITGA4C1RNPC1TP53 | |
| SCHEMBL2433737 | 0.89 | ITGB1 (0.57) | ITGB1ITGA4C1R | |
| SCHEMBL2431856 | 0.87 | ITGB1 (0.57) | ITGB1ITGA4 | |
| SCHEMBL2432759 | 0.87 | ITGB1 (0.58) | ITGB1ITGA4 | |
| SCHEMBL2433688 | 0.87 | ITGB1 (0.57) | ITGB1ITGA4C1RNPC1RAB9A | |
| SCHEMBL2433474 | 0.87 | C1R (0.52) | ITGB1ITGA4C1RPTGS2NPC1 | |
| SCHEMBL2433190 | 0.87 | ITGB1 (0.45) | ITGB1ITGA4C1RNPC1RAB9A | |
| SCHEMBL2432841 | 0.85 | ITGB1 (0.49) | ITGB1ITGA4 | |
| SCHEMBL2430157 | 0.83 | PTGS2 (0.52) | ITGB1ITGA4C1RPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | ITGB1 5/4885ITGA4 4/4885C1R 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.